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Abstract: Serotonin signalling in the heart is mediated by receptor subtype 2B (5-HTR2B). A 
contribution of serotonin to valvular disease is reported, but myocardial expression of 5-HTR2B and its 
role in canine dilated cardiomyopathy (DCM) is not known. The aim of this study was to investigate 
myocardial 5-HTR2B mRNA expression in dogs with DCM and to correlate results with expression of 
markers for inflammation and remodelling. Myocardial samples from eight healthy dogs, four dogs 
with DCM, five dogs with cardiac diseases other than DCM and six dogs with systemic non-cardiac 
diseases were investigated for 5-HTR2B mRNA expression using quantitative PCR (qPCR). The results 
were compared to mRNA expression of selected cytokines, matrix metalloproteinases (MMP) and 
tissue inhibitors of matrix metalloproteinase (TIMP). Laser microdissection with subsequent qPCR and 
immunohistochemistry were employed to identify the cells expressing 5-HTR2B. The myocardium of 
control dogs showed constitutive 5-HTR2B mRNA expression. In dogs with DCM, 5-HTR2B mRNA 
values were significantly greater than in all other groups, with highest levels of expression in the left 
ventricle and right atrium. Myocytes were identified as the source of 5-HTR2B mRNA and protein. A 
significant positive correlation of 5-HTR2B with expression of several cytokines, MMPs and TIMPs was 
observed. These findings suggest that serotonin might play a role in normal cardiac structure and 
function and could contribute to myocardial remodelling and functional impairment in dogs with DCM. 
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Abstract 29 
Serotonin signalling in the heart is mediated by receptor subtype 2B (5-HTR2B). A 30 
contribution of serotonin to valvular disease is reported, but myocardial expression of 5-31 
HTR2B and its role in canine dilated cardiomyopathy (DCM) is not known. The aim of this 32 
study was to investigate myocardial 5-HTR2B mRNA expression in dogs with DCM and to 33 
correlate results with expression of markers for inflammation and remodelling. Myocardial 34 
samples from eight healthy dogs, four dogs with DCM, five dogs with cardiac diseases other 35 
than DCM and six dogs with systemic non-cardiac diseases were investigated for 5-HTR2B 36 
mRNA expression using quantitative PCR (qPCR). The results were compared to mRNA 37 
expression of selected cytokines, matrix metalloproteinases (MMP) and tissue inhibitors of 38 
matrix metalloproteinase (TIMP). Laser microdissection with subsequent qPCR and 39 
immunohistochemistry were employed to identify the cells expressing 5-HTR2B. The 40 
myocardium of control dogs showed constitutive 5-HTR2B mRNA expression. In dogs with 41 
DCM, 5-HTR2B mRNA values were significantly greater than in all other groups, with 42 
highest levels of expression in the left ventricle and right atrium. Myocytes were identified as 43 
the source of 5-HTR2B mRNA and protein. A significant positive correlation of 5-HTR2B 44 
with expression of several cytokines, MMPs and TIMPs was observed. These findings 45 
suggest that serotonin might play a role in normal cardiac structure and function and could 46 
contribute to myocardial remodelling and functional impairment in dogs with DCM. 47 
 48 
Keywords: Serotonin, Heart failure, Cardiac disease, Dilated cardiomyopathy, Myocardial 49 
remodelling 50 
  51 
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Introduction 52 
Serotonin (5-hydroxytryptamine; 5-HT) is a monoamine neurotransmitter, which is 53 
produced from tryptophan by two different tryptophan hydroxylases (TPH), namely, TPH1 54 
and TPH2, found in enterochromaffine cells of the gastrointestinal tract and in neurons of the 55 
central nervous system, respectively (Jonnakuty and Gragnoli, 2008). Serotonin is involved in 56 
platelet function, vascular and non vascular smooth muscle contraction as well as cardiac 57 
function (Nebigil and Maroteaux, 2003; Jonnakuty and Gragnoli, 2008). It is rapidly removed 58 
from the circulation, via cellular uptake by the serotonin transporter (SERT) and 59 
subsequently stored in platelets or metabolised in pulmonary vascular endothelial cells and 60 
hepatocytes by monoamine oxidase (Jonnakuty and Gragnoli, 2008). However, high 61 
circulating 5-HT concentrations or administration of serotonergic drugs are associated with 62 
arrhythmia and valvulopathy (Sheline et al., 1997; reviewed by Kaumann and Levy, 2006; 63 
Elangbam et al., 2008; Orton et al., 2012). Furthermore, 5-HT is suspected to be involved in 64 
myxomatous valvular disease (MVD) in humans and dogs (Fitzgerald et al., 2000; Arndt et 65 
al., 2009; Oyama and Levy, 2010).  66 
 67 
Serotonin exerts its effect through seven different receptor groups (5-HTR1 to 5-68 
HTR7), composed of several receptor subtypes (Elangbam et al., 2005; Kaumann and Levy, 69 
2006), all of which are members of the G-protein-coupled receptor superfamily. In the 70 
cardiovascular system, the receptor subtypes 5-HTR1B, 2A, 2B, 4 and 7 can be found, of 71 
which the receptor subtype 5-HTR2B, which is present on endothelial cells, smooth muscle 72 
cells, fibroblasts, valvular interstitial cells and cardiomyocytes, is suspected to be involved in 73 
cardiac remodelling and development of valvulopathies (Rothman et al., 2000; Kaumann and 74 
Levy, 2006; Disatian and Orton, 2009; Oyama and Levy, 2010; Hutcheson et al., 2011). 75 
 76 
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Activation of 5-HTR2B has been found to stimulate phospholipase C and A2, both of 77 
which increase the intracellular calcium concentration. In addition, downstream signalling, 78 
involving extracellular-signal regulated kinase (ERK), mediates proliferative effects by 79 
inducing transcription of transforming growth factor (TGF)-β and other effector genes, such 80 
as matrix metalloproteinases (MMP) and bone morphogenic protein, which potentially 81 
contribute to the pathogenesis of mitral valve disease (Disatian and Orton, 2009; Lacerda et 82 
al., 2012a; Orton et al., 2012). Furthermore, activation of 5-HTR2B has been shown to 83 
increase expression of interleukin (IL)-1, IL-6 and tumor necrosis factor alpha (TNF-α) 84 
mRNA and protein in murine cardiac fibroblasts (Jaffre et al., 2004). These inflammatory 85 
cytokines are known to be elevated in the blood of humans and dogs affected with congestive 86 
heart failure (CHF) and are involved in cardiac inflammation and remodelling (Anker and 87 
von Haehling, 2004; Fonfara et al., 2011). Tensile strain has been suspected to increase TPH 88 
and 5-HTR2B and reduce SERT in canine septal mitral valve leaflets, which might result in 89 
local 5-HT synthesis and prolonged 5-HT activity (Elangbam et al., 2008; Scruggs et al., 90 
2010; Lacerda et al., 2012a; Lacerda et al., 2012b). 91 
 92 
The role of 5-HT and its receptors in canine DCM is not fully understood. Dilated 93 
cardiomyopathy is associated with left ventricular dilatation and ventricular wall thinning, 94 
therefore increasing wall stress. Increased ventricular wall stress is likely to stimulate 95 
mechanoreceptors, which could cause local 5-HT production and increased 5-HTR2B 96 
expression, as reported for valve leaflets exposed to tensile strain (Disatian and Orton, 2009; 97 
Lacerda et al., 2012b). This appears likely, since in rats, chronic 5-HT administration has 98 
been shown to increase valvular 5-HTR2B transcription (Elangbam et al., 2008). In humans 99 
with heart failure, 5-HT plasma concentrations are also elevated, which has led to the 100 
assumption that heart failure is mediated by 5-HTR2B (Jaffre et al., 2009; Shyu, 2009). 101 
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 102 
It is suspected that through induction of IL-1, IL-6, TNF-α and TGF-β1, 5-HT 103 
contributes to cardiomyocyte hypertrophy, increased fibrosis and ventricular stiffness leading 104 
to reduced cardiac contractility and heart disease (Anker and von Haehling, 2004; Jaffre et 105 
al., 2004: Disatian and Orton, 2009; Jaffre et al., 2009). Increased concentrations of TGF-β1, 106 
a potent profibrotic cytokine, have been reported in canine MVD (Aupperle et al., 2008; 107 
Disatian and Orton, 2009) and CHF (Fonfara et al., 2011). We have recently shown that dogs 108 
with end-stage cardiac diseases exhibit increased myocardial mRNA expression of 109 
inflammatory cytokines, TGF-β1, MMP-2 as well as tissue inhibitor of matrix 110 
metalloproteinase (TIMP)-1 and TIMP-2 (Fonfara et al., 2013a; Fonfara et al., 2013b). 111 
Considering these results and the characteristic pathological changes in canine DCM, we 112 
hypothesize that the 5-HT system plays a role in the pathogenesis of canine DCM. We 113 
therefore designed a study to investigate cardiac expression of 5-HTR2B and its association 114 
with expression of IL-1, IL-6, TNF-α, TGF-β1, MMP-1, -2, -3, -13, TIMP-1 and -2, 115 
comparing healthy control dogs with other groups of dogs affected with DCM, other cardiac 116 
diseases or systemic non-cardiac disease. 117 
 118 
Material and methods 119 
Animals and tissues 120 
Details of clinical cases are shown in Table 1 and consist of dogs affected with DCM 121 
(group 2; n = 4), cardiac diseases other than DCM (group 3; n = 5) and dogs with systemic, 122 
non-cardiac disease (group 4; n = 6) (Fonfara et al., 2013a; Fonfara et al., 2013b). Eight 123 
control Beagles (group 1a) were used for the quantitative PCR assay (four each entire male 124 
and female, sourced from a pharmaceutical company with a median age of 2.75 years). The 125 
dogs were euthanized and post-mortem examination performed on site. Samples from the 126 
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myocardium (left and right atrium [LA, RA], left and right ventricle [LV, RV]) were 127 
immersed in RNAlater (Ambion) and provided for this project. Two Doberman Pinscher dogs 128 
(one female neutered 2 years old, one male entire 6 years old), with no gross or histological 129 
evidence of cardiac disease, served as controls for the immunohistological examination 130 
(group 1b).  131 
 132 
All of the dogs with cardiac and systemic diseases were clinical cases that had 133 
undergone diagnostic investigations according to their underlying disease and presenting 134 
clinical signs. Investigations were performed by clinical specialists in their respective fields 135 
or board-registered residents under supervision. For cardiac cases, investigations included a 136 
cardiac work-up, comprising blood pressure measurement, electrocardiography, 137 
echocardiography and thoracic radiography, at different time points prior to death (Fonfara et 138 
al., 2013b). Diagnoses were made, based on applying standardised criteria for clinical 139 
assessment of cardiac cases. For classification of heart failure, the ABCD scheme was used 140 
(Strickland, 2008). Dogs had been euthanized upon owners’ request, due to poor prognosis 141 
and impaired quality of life, with one exception, where a dog developed ventricular 142 
fibrillation and died (Fonfara et al., 2013b). Informed consent was obtained from owners 143 
prior to inclusion into the study and samples were anonymised by assigning identification 144 
numbers. The study was approved by the University of Bristol Committee on Research 145 
Ethics. 146 
 147 
Hearts were removed within 1 h of death and examined for any gross pathological 148 
abnormalities. Myocardial samples (interventricular septum [IVS], RA, RV, LA, LV) were 149 
collected and stored in RNAlater at -20 °C until use. Hearts were subsequently fixed in 10% 150 
formalin for a minimum of 48 h and tissue samples from the same sites as those for RNA 151 
Comment [l1]: I have removed the 
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extraction were prepared and paraffin wax embedded, according to routine procedures for 152 
histological and immunohistological examinations. The hearts from the immunohistology 153 
control dogs (group 1b) were formalin-fixed and subsequently processed as for the other 154 
hearts. 155 
 156 
Laser microdissection 157 
A left ventricular sample from a dog with DCM stored in RNAlater was embedded in 158 
OCT compound (Tissue-Tek) and frozen at -40 °C. Cryosections (8-10 μm) were prepared 159 
and placed onto specific membrane slides (Carl Zeiss), which had been incubated in dry heat 160 
at 180 °C for 4 h prior to use, in order to inactivate RNase enzymes. The slides with 161 
cryosections were air dried, stained with haematoxylin as recommended by the manufacturer 162 
(Carl Zeiss) and immediately used.  163 
 164 
Cardiomyocytes were isolated with a Zeiss Palm microbeam laser microdissection 165 
microscope, using a 40× lens. Cutting was performed with 52-55% energy, 60-62% focus and 166 
10% speed and collection with 65% energy and 47% focus. Three samples of approximately 167 
100-150 cardiomyocytes were collected into a 500 μL adhesive cap tube (Carl Zeiss). After 168 
collection, tissue was lysed into 50 μL RLT buffer containing 2-mercaptoethanol (Qiagen). 169 
Samples were subsequently frozen at -20 °C for 18-22 h and subsequently RNA isolation was 170 
performed using the RNeasy Minikit (Qiagen). 171 
 172 
Quantitative assessment of 5-HTR2B mRNA expression 173 
Total RNA was extracted from myocardial samples and cDNA synthesized as reported 174 
previously (Fonfara et al., 2011b). For the samples obtained by laser microdissection, 14 μL 175 
RNase-free water was used to elute RNA from the column prior to cDNA synthesis. The 176 
Comment [l2]: Otherwise it is double? 
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forward and reverse Published pprimer sequences were used for the canine housekeeping 177 
gene GAPDH were 5’CTGGGGCTCACTTGAAAGG3’ and 178 
5’CAAACATGGGGGCATCAG3’, respectively, and for 5-HTR2B 179 
5’CCCAATGAGGCTCTGCAGTT3’ and 180 
5’CTGTGATGAGAAGTGTATCTAGTAGAATGATT3’, respectively. and 5-HTR2B 181 
[Editor comment: might be better to put primer sequences here. You reference three 182 
publications for two primer pairs] (Oyama and Chittur, 2006; Fonfara et al., 2013a; Fonfara 183 
et al., 2013b). The primer efficiency of the GAPDH primer pair was 100% and of 5-HTR2B 184 
97%. PCR was performed and analyzed according to standard protocols, the expression of 5-185 
HTR2B was normalized to GAPDH expression (relative expression) and calculated via the 2
–186 
ΔΔCt
 method, as previously reported (Fonfara et al., 2013a; Fonfara et al., 2013b). 187 
 188 
Statistical analysis and correlation of 5-HTR2B mRNA with cytokine, MMP and TIMP 189 
expression 190 
For the statistical analysis of the quantitative PCR results, Minitab 16 was used. 191 
Following performance of basic descriptive statistics, 5-HTR2B mRNA values were log 192 
transformed to improve normality and the model assumptions necessary for parametric 193 
analysis. For comparison of different groups and/or cardiac regions, one-way ANOVA tests 194 
were employed. Results are displayed as mean and standard deviation. 195 
 196 
To test for a potential correlation between 5-HTR2B and cytokine, MMP or TIMP 197 
expression in the hearts of dogs with DCM, the qPCR results for IL-1, IL-6, TNF-α, TGF-β1, 198 
MMP-1, 2, -3, -13, TIMP-1 and TIMP-2, obtained from the same myocardial samples, were 199 
used (Fonfara et al., 2013a; Fonfara et al., 2013b). Expression was examined with scatterplots 200 
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and then tested with the Pearson correlation test. Statistical significance was defined as P < 201 
0.05. 202 
 203 
Histology and immunohistochemistry 204 
For the histological examination, 3-5 μm thick sections were prepared from the paraffin 205 
wax-embedded tissue blocks and stained with haematoxylin and eosin (HE). 206 
Immunohistochemistry for 5-HTR2B was performed on sections from the RA and the RV 207 
and/or LV using a murine anti-human 5-HTR2B antibody (clone A72-1; Beckton Dickinson) 208 
and the horseradish peroxidase method (HRP mouse kit, Dako), following antigen retrieval 209 
by incubation in citrate buffer (pH 6.0) and microwaving (Disatian and Orton, 2009). 210 
Consecutive sections were incubated with an isotype-control mouse monoclonal antibody and 211 
sections from canine stomach, tissue from a case of suppurative myocarditis and smooth 212 
muscle cells present in myocardial arteries served as positive controls. 213 
 214 
Results 215 
Pathology and histopathology 216 
The hearts of dogs with systemic diseases and clinical diagnoses of cardiac diseases 217 
other than DCM did not exhibit any gross or histological changes, i.e. there was no evidence 218 
of degenerative, neoplastic or inflammatory changes (Fonfara et al., 2013b). The hearts of 219 
dogs with DCM showed the typical gross changes (cardiomegaly, biventricular dilatation, 220 
myocardial eccentric hypertrophy). Histologically, interstitial, subendo- and subepicardial 221 
fibrosis, lipomatosis cordis, leukocyte infiltration, and focal cardiomyocyte necrosis was 222 
observed, as previously reported (Fonfara et al., 2013b). 223 
 224 
Canine cardiac 5-HTR2B expression 225 
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Expression of 5-HTR2B mRNA was detected in the myocardium of control dogs in all 226 
examined locations (RA, RV, LA, LV), with some individual variation in quantitative values 227 
(Fig. 1). In the other groups, 5-HTR2B expression was also consistently observed, including 228 
in the IVS, which was not available for examination in control dogs. There was a greater 229 
individual variation in the disease groups (Table 2), although for groups 3 and 4, 5-HTR2B 230 
values did not differ significantly from those of control dogs. In contrast, dogs with DCM 231 
(group 2) demonstrated significantly greater 5-HTR2B mRNA expression when compared to 232 
all other groups (Table 2). 233 
 234 
The results of the RT-PCR performed on isolated cardiomyocytes of the LV of a dog 235 
affected with DCM, showed that the cardiomyocytes were expressing 5-HTR2B mRNA and 236 
the immunohistochemical staining of both control and diseased dogs confirmed that 237 
cardiomyocytes also synthesised 5-HTR2B protein (Fig. 2). Immunohistochemistry showed 238 
5-HTR2B protein expression not only in cardiomyocytes, but also in vascular smooth muscle 239 
cells and infiltrating as well as intravascular neutrophils (Fig. 2). Immunostaining in 240 
cardiomyocytes was generally weak and often patchy or with negative fibers intermingled 241 
with positive fibers. However, staining in cardiomyocytes was generally most intense in the 242 
right atrium, a finding that was supported by the general trend for greatest mRNA expression 243 
at this location (Fig. 1). 244 
 245 
Disease-associated differences in 5-HTR2B mRNA expression values concentrations and 246 
patterns 247 
A comparison of 5-HTR2B mRNA values concentrations in the different groups 248 
showed comparable expression levels in controls dogs and those with cardiac diseases other 249 
than DCM, or dogs with systemic diseases (P = 0.46). However, in dogs with DCM, mRNA 250 
Comment [l4]: One of the reviewers did 
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values concentrations were significantly greater than in all other groups (P = 0.002; Fig. 1). 251 
This difference was primarily due to greater 5-HTR2B mRNA values concentrations in the 252 
LV (P = 0.005) and the RA (P = 0.027) of dogs with DCM, when the different cardiac 253 
regions were compared between groups. In dogs with DCM, the same significant difference 254 
in 5-HTR2B mRNA (P = 0.001) was observed between the different regions, with 5-HTR2B 255 
mRNA concentrations values in the RA also being significantly higher than in the LV (P = 256 
0.047; Fig. 1). None of the other groups exhibited significant differences in mRNA 257 
concentrations values comparing different cardiac locations. 258 
 259 
The immunohistochemical results confirmed the mRNA expression data, since staining 260 
of cardiomyocytes for 5-HTR2B was more consistent and more intense in the RA, compared 261 
to other locations in the DCM dogs, and compared to the same location in dogs from other 262 
groups (Fig. 2B, C). 263 
 264 
Correlation between 5-HTR2B and cytokine, MMP and TIMP expression in the myocardium 265 
of dogs with DCM 266 
We have previously shown upregulation of cytokine, MMP and TIMP mRNA 267 
expression in the myocardium of dogs with DCM (Fonfara et al., 2013a; Fonfara et al., 268 
2013b). Using the qPCR data generated from the same RNA extracts and applying the 269 
Pearson’s correlation test, a significant positive correlation was seen between 5-HTR2B 270 
mRNA expression and IL-1 (r = 0.719, P < 0.001; Fig. 3a), IL-6 (r = 0.624, P = 0.003), TNF-271 
α (r = 0.661, P = 0.002), TGF-β1 (r = 0.848, P < 0.001; Fig. 3b), MMP-2 (r = 0.493, P = 272 
0.027), MMP-13 (r = 0.770, P < 0.001; Fig. 3a), TIMP-1 (r = 0.729, P < 0.001; Fig. 3b) and 273 
TIMP-2 (r = 0.826, P < 0.001). [Editor comment: should you add an additional figure to 274 
illustrate this data ? What are the r values ?] 275 
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 276 
Discussion 277 
The present study assesses the constitutive expression of 5-HTR2B in the myocardium 278 
of dogs and the changes in expression pattern and intensity in association with canine DCM. 279 
The examination of control dogs showed that the myocardium constitutively expresses 5-280 
HTR2B, suggesting a role for 5-HT and its cardiac receptor in normal cardiac structure and 281 
function (Nebigil et al., 2001; Nebigil et al., 2003; Liang et al., 2006). There were no 282 
significant differences in regional expression of 5-HTR2B mRNA, but a trend for higher 283 
expression in the RA was observed.  284 
 285 
Our results indicate that severe systemic diseases and non-DCM cardiac diseases do not 286 
influence 5-HTR2B expression, whereas canine DCM is associated with a significant 287 
increase in the RA and, to a lesser, but still significant extent, the LV. This 5-HTR2B 288 
upregulation correlated with increased IL-1, IL-6, TNF-α, TGF-β1, MMP-2, MMP-13, 289 
TIMP-1 and TIMP-2 mRNA expression. Using laser microdissection and immunohistology, 290 
we were able to confirm that cardiomyocytes synthesize 5-HTR2B, which is similar to 291 
previously reported results for canine MVD and cardiomyocytes in mice and humans (Choi 292 
and Maroteaux, 1996; Kaumann and Levy, 2006; Liang et al., 2006; Disatian and Orton, 293 
2009; Oyama and Levy, 2010; Orton et al., 2012). 294 
 295 
Serotonin, in association with increased 5-HTR2B and reduced SERT production, has 296 
been reported in dogs with MVD (Oyama and Chittur, 2006; Arndt et al., 2009; Disatian and 297 
Orton, 2009; Scruggs et al., 2010). The results of the present study indicate that 5-HTR2B 298 
also plays a role in canine DCM. In contrast to the results of the current study, in mouse 299 
models of DCM, reduced 5-HTR2B protein expression was observed, whereas increased 5-300 
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HTR2B expression caused cardiac hypertrophy (Nebigil et al., 2001; Nebigil et al., 2003). 301 
Since the dogs with DCM in our study exhibited ventricular eccentric hypertrophy and were 302 
all in decompensated CHF, these results may not be entirely contradictory, but are on the 303 
other hand not fully comparable. 304 
 305 
In humans, CHF has been shown to be associated with an increase of 5-HT 306 
independently of the type of cardiac disease (Jaffre et al., 2009). Since chronic 5-HT 307 
administration results in increased 5-HTR2B expression (Elangbam et al., 2008), it is 308 
possible that 5-HT is also chronically elevated in dogs that develop DCM, resulting in 309 
increased 5-HTR2B transcription, thereby suggesting that CHF and not the underlying 310 
cardiac disease is responsible for the increase of 5-HT and its receptor. However, if high 5-311 
HT concentrations would be the cause of 5-HTR2B upregulation in DCM, it can be expected 312 
that all regions investigated and not just the RA and LV would increase 5-HTR2B gene 313 
expression. Instead, our results suggested local changes in the 5-HT system, and upregulation 314 
of 5-HTR2B in the LV (which is mainly affected in canine DCM) further supports this 315 
hypothesis.  316 
 317 
Interestingly in humans, administration of a 5-HT re-uptake inhibitor has been reported 318 
to cause DCM and cardiogenic shock, but myocardial 5-HTR2B was not investigated in this 319 
patient (Charniot et al., 2010). It is also possible that an increase of TPH1 and phosphorylated 320 
ERK, or a reduction of SERT would result in enhanced serotonin production and signalling, 321 
as reported for valvular diseases (Elangbam et al., 2008; Disatian and Orton, 2009; Scruggs et 322 
al., 2010; Lacerda et al., 2012a; Lacerda et al., 2012b). Further investigations, in particular 323 
assessment of circulating serotonin concentrations and the myocardial signal transduction 324 
pathway, would be needed to confirm this. The lack of evidence of increased 5-HTR2B gene 325 
14 
 
expression in dogs with cardiac diseases other than DCM might be a consequence of the case 326 
selection, i.e. dogs with a variety of cardiac diseases other than DCM were included into this 327 
group. 328 
 329 
We identified a positive correlation between 5-HTR2B expression and IL-1, IL-6, TNF-330 
α, TGF-β1, MMP-2, MMP-13, TIMP-1 and TIMP-2 mRNA in the myocardium of dogs with 331 
DCM. Others have reported that 5-HT can induce IL-1, IL-6, TNF-α, TGF-β1, MMP-1, 332 
MMP-3 and MMP-13 (Jaffre et al., 2004; Yabanoglu et al., 2009; Lacerda et al., 2012b). The 333 
inflammatory cytokines IL-1, IL-6 and TNF-α are important mediators of myocardial 334 
inflammation and affect myocardial contractility (Anker and von Haehling, 2004). The 335 
cytokine TGF-β1 mediates growth of cardiomyocytes (Schultz et al., 2002) and is suspected 336 
to impair mitochondrial energy metabolism (Huntgeburth et al., 2011) and might therefore be 337 
involved in eccentric cardiac hypertrophy and contribute to systolic dysfunction in dogs with 338 
DCM and CHF. Furthermore, myofibroblast activation by TGF-β1 alongside mechanical 339 
strain is suspected to lead to increased stiffening of heart valves (Orton et al., 2012), and 340 
could also be involved in increased ventricular stiffness and functional impairment in dogs 341 
with DCM and CHF. 342 
 343 
Matrix metalloproteinases and TIMPs are important regulators of cardiac remodeling 344 
(Spinale, 2007). It has been reported that 5-HT induces MMP-3 and MMP-13 expression in 345 
cardiac fibroblasts (Yabanoglu et al., 2009) and an increased MMP-1 and MMP-13 protein 346 
production in mitral valve leaflets exposed to tensile strain was suspected to be caused by 5-347 
HTR2B stimulation (Lacerda et al., 2012a; Lacerda et al., 2012b). In the present study, a 348 
significant positive correlation of 5-HTR2B with MMP-2, MMP-13, TIMP-1 and TIMP-2 349 
expression was detected in myocardial samples of dogs with DCM and CHF. Matrix 350 
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metalloproteinase 2, a gelatinase, and MMP-13, a collagenase, might be involved in matrix 351 
degradation and ventricular dilatation, whereas TIMP-1 and -2 might contribute to increased 352 
fibrosis and ventricular stiffness in these dogs (Spinale, 2007). 353 
 354 
Increased 5-HTR2B mRNA expression in the RA and the further increase in dogs with 355 
DCM is of interest. In humans, elevated 5-HT concentrations have been reported to cause 356 
pathological changes in the right heart valves, whereas the left heart valves are presumed to 357 
be protected by 5-HT breakdown by pulmonary monoamine oxidase (Hutcheson et al., 2011). 358 
Additionally, increased 5-HT concentrations have been shown to produce arrhythmia, 359 
including atrial fibrillation (AF) (Sheline et al., 1997). An increase of 5-HTR2B in the RA 360 
might reflect enhanced 5-HT signalling. This would contribute to the structural remodelling 361 
of the RA, which is an important factor in the development of AF (Brundel et al., 2005). 362 
Also, we recently reported increased expression of IL-1, TNF-α and TGF-β1 in the RA and of 363 
MMP-2 and MMP-13 in both atria of dogs with AF (Fonfara et al., 2013a; Fonfara et al., 364 
2013b). TGF-β1 is known to modulate atrial ion channels, potential promoting AF (Ramos-365 
Mondragon et al., 2011) and MMP-2 and -13 might cause atrial dilatation, which is 366 
frequently associated with AF. Therefore, increased 5-HTR2B expression in the RA, together 367 
with upregulation of inflammatory cytokines, TGF-β1, MMP-2 and -13 might contribute to 368 
development of AF, a clinical feature observed in three of the four dogs with DCM.  369 
 370 
Arrhythmia might also be caused by 5-HTR2B-induced activation of phospholipase C 371 
and A2, which results in an increase in intracellular calcium concentration and disrupted 372 
calcium handling (Hutcheson et al., 2011). This might be one of the mechanisms underlying 373 
reduced myocardial function observed in dogs with DCM and CHF (Martin et al., 2009; 374 
Oyama et al., 2009). 375 
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 376 
The study has a number of limitations, including the small number of dogs used, the 377 
heterogeneity of groups 3 and 4 and the age difference between the control animals and those 378 
in the other groups. Larger sample sizes and groups with more homogeneous phenotypes 379 
would have allowed a comparison of different cardiac diseases and might have provided 380 
more significant results. Investigation of 5-HTR2B expression in isolation, without studying 381 
further components of the signal transduction pathway, limits interpretation of the study 382 
findings, in terms of how receptor upregulation might impact on cellular responses. However, 383 
a positive correlation of 5-HTR2B expression with increased expression of the downstream 384 
gene products of the signal transduction pathway was present. Only dogs with end-stage 385 
diseases were included, which also excluded investigation of the involvement of 5-HTR2B in 386 
progression of DCM. 387 
 388 
Conclusions 389 
Constitutive expression of 5-HTR2B mRNA in myocardial samples of young Beagle 390 
dogs suggests an involvement of 5-HT and its receptor in normal cardiac structure and 391 
function. Increased 5-HTR2B mRNA expression and a positive correlation with IL-1, IL-6, 392 
TNF-α, TGF-β1, MMP-2, MMP-13, TIMP-1 and TIMP-2 in dogs with DCM and CHF 393 
suggests a contribution of 5-HT to structural myocardial remodelling and functional 394 
impairment in these dogs. Further investigations of the role of 5-HT, its receptor and the 395 
signal transduction pathway in the progression of canine DCM are needed in particular to 396 
investigate any potential therapeutic implications. 397 
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Table 1. Details of dogs in each of the study groups. 584 
Study 
group 
Breed 
Age 
(years) 
Sex Disease 
CHIEF 
classification 
BW  
(kg) 
AF  
(Y/N) 
2 Doberman 10 NF 
Dilated 
cardiomyopathy 
D 34.8 Y 
2 Doberman 8 F 
Dilated 
cardiomyopathy 
D 39.6 Y 
2 Bullmastiff 7 M 
Dilated 
cardiomyopathy 
D 54 N 
2 
Great 
Dane 
6 M 
Dilated 
cardiomyopathy 
D 70.8 Y 
3 Boxer 11 M Aortic stenosis B 26 N 
3 Labrador 0.2 M Tricuspid dysplasia C3 7.8 N 
3 Labrador 9 NF Pulmonic stenosis B 32.5 N 
3 Labrador 6 NM 
Arrhythmogenic 
cardiomyopathy 
C3 32 N 
3 
German 
Shepherd 
14 NF 
Myxomatous 
valvular disease 
D 22.7 Y 
4 Boxer 7.5 M Brain tumour - 37.5 N 
4 Cocker 8 NF Brain tumour - 14.4 N 
4 Cross 7 NF Lymphoma - 9.6 N 
4 Cross 11 NF 
Pancreatic 
carcinoma 
- 20.5 N 
4 Rottweiler 0.75 M 
Secondary 
hyperparathyroidism 
- 24.55 N 
4 Labrador 0.5 M Spinal fracture - 27.3 N 
 585 
CHIEF, Canine Heart Failure International Expert Forum; AF, atrial fibrillation; BW, body 586 
weight; CHF, congestive heart failure; F, female; M, male; N, no; NF, neutered female; NM, 587 
neutered male; Y, yes. 588 
589 
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Table 2. Relative 5-HTRB2 mRNA expression in different myocardial regions of control 590 
dogs (group 1), dogs with dilated cardiomyopathy (group 2), those with cardiac diseases 591 
other than dilated cardiomyopathy (group 3) and those with systemic non-cardiac diseases 592 
(group 4). Results are displayed as mean (top value) and standard deviation (bottom value).  593 
 594 
Region 
Group 1 
(n = 8) 
Group 2 
(n = 4) 
Group 3 
(n = 5) 
Group 4 
(n = 6) 
Interventricular 
septum 
n.d. 
1.64 
(0.44)
 1
 
1.37 
(0.46) 
1.34 
(0.50) 
Left atrium 
1.39 
(0.37) 
1.62 
(0.26)
 1
 
1.40 
(0.33) 
1.32 
(0.49) 
Left ventricle 
1.47 
(0.20) 
2
 
2.12 
(0.26)
 1,2
 
1.20 
(0.36)
 2
 
1.22 
(0.55)
 2
 
Right atrium 
1.97 
(0.42)
 3
 
2.89 
(0.55)
 1,3 
1.52 
(0.90)
 3
 
2.02 
(0.57)
 3 
Right ventricle 
1.27 
(0.54) 
1.54 
(0.34)
 1
 
1.46 
(0.46) 
1.08 
(0.57) 
All samples 
1.54 
(0.45)
 4
 
1.96 
(0.62)
 4
 
1.39 
(0.60)
 4
 
1.40 
(0.60)
 4
 
 595 
Significant difference between results: 
1
 P = 0.001, 
2
 P = 0.005, 
3
 P = 0.027, 
4
 P = 0.002. 596 
n.d., not determined. 597 
1
 A significant difference in 5-HTRB2 mRNA expression was present comparing cardiac 598 
regions of group 2 (P = 0.001). 599 
2,3
 5-HTRB2 mRNA expression was greater in the left ventricle (
2
 P = 0.005) and right atrium 600 
(
3
 P = 0.027) of dogs from group 2, comparing these regions between groups.  601 
4
 A significant difference in 5-HTRB2 mRNA expression was present comparing all samples 602 
of the different groups (P = 0.002). 603 
 [Editor comment: what does # represent ? Can you be more precise about what the statistics 604 
represent?] 605 
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Figure Legends 607 
 608 
Fig. 1. Relative 5-HTR2B2 mRNA expression (normalized to GAPDH expression) in 609 
myocardial samples of different cardiac regions [interventricular septum (IVS), left atrium 610 
(LA), left ventricle (LV), right atrium (RA) right ventricle (RV)] comparing control dogs 611 
(group 1, n = 8), dogs with dilated cardiomyopathy (group 2, n = 4), dogs with cardiac 612 
diseases other than dilated cardiomyopathy (group 3, n = 5) and dogs with systemic non-613 
cardiac diseases (group 4, n = 6). Significantly greater 5-HTR2B mRNA expression was 614 
present in left ventricular and right atrial samples of dogs with DCM (P < 0.05). Individual 615 
value plot with mean  and median . [Editor comment: Is the data normally distributed (I 616 
assume not) in which case it might be better just to have a median line. You need a y-axis 617 
label.] 618 
 619 
Fig. 2. Immunohistochemical analysis of 5-HTR2B protein expression in the myocardium of 620 
the right atrium. A) Control dog. Cardiomyocytes exhibiting a weak positive cytoplasmic 621 
reaction for 5-HTR2B (arrows) are found close to negative cardiomyocytes (arrowheads). B) 622 
Dog with DCM. All cardiomyocytes exhibit moderate cytoplasmic staining with an intensity 623 
similar to that seen in smooth muscle cells of small arterial walls (arrow). C) Dog with severe 624 
pulmonary stenosis. Bundles of weakly positive cardiomyocytes are seen adjacent to 625 
aggregates of negative cardiomyocytes (arrowheads). Arrow: small artery. D) Dog with brain 626 
tumour. Cardiomyocytes exhibit a weak cytoplasmic reaction. Arrow: small artery. 627 
Horseradish peroxidase method, Papanicolaou’s haematoxylin counterstain. Bar = 20 µm.   628 
 629 
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Fig. 3. Scatter plots showing a positive correlation between 5-HTR2B mRNA expression and 630 
IL-1 (r = 0.719, P < 0.001), MMP-13 (r = 0.770, P < 0.001) (3a), TGF-β (r = 0.848, P < 631 
0.001) and TIMP-1 (r = 0.729, P < 0.001) (3b) mRNA concentrations.  632 
Editor comment: is it worthwhile illustrating the correlation data, comparing 5-HTRB2 with 633 
cytokine, MMP and TIMP values. 634 
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